Luteinizing Hormone (DB14741): A Comprehensive Endocrinological and Pharmacological Review

Executive Summary

Luteinizing Hormone (LH) is a pivotal gonadotropin hormone, classified as a biotech drug (DrugBank ID: DB14741, CAS: 9002-67-9), that is indispensable for mammalian reproduction.[1] Secreted by the anterior pituitary gland, it executes a dual function critical for sexual development and fertility. In males, LH stimulates the Leydig cells of the testes to produce testosterone, the principal androgen essential for spermatogenesis and the maintenance of male characteristics. In females, it orchestrates the menstrual cycle, culminating in an acute surge that triggers ovulation and subsequently promotes the corpus luteum's production of progesterone to support potential pregnancy.[3]

Therapeutically, LH is available in two main classes: urinary-derived menotropins, which contain a mixture of LH and follicle-stimulating hormone (FSH), and the highly purified recombinant human LH (r-hLH), lutropin alfa, which offers superior purity and batch-to-batch consistency.[6] Its primary clinical application is in treating infertility, particularly in the niche population of women with hypogonadotropic hypogonadism who have a profound LH deficiency.[6] While clinical data comparing recombinant and urinary-derived formulations show nuanced results depending on the patient population, economic analyses suggest that the higher efficacy of recombinant LH can lead to greater cost-effectiveness by reducing the total cost per live birth.[10] The safety profile of LH therapy is well-characterized, with Ovarian Hyperstimulation Syndrome (OHSS) being the most significant iatrogenic risk, necessitating careful patient monitoring and management.[13] The therapeutic landscape for targeting the LH pathway continues to expand beyond reproduction, with LH-releasing hormone (LHRH) analogues established as a cornerstone of androgen deprivation therapy in oncology and emerging research implicating LH in the pathophysiology of neurodegenerative diseases.[15]

Molecular Profile and Physiological Role of Luteinizing Hormone

Structure and Biosynthesis

Luteinizing Hormone (LH) is a heterodimeric glycoprotein hormone synthesized and secreted by the gonadotropic cells of the anterior pituitary gland.[3] These specialized cells, which make up 10-15% of the anterior pituitary's functional cell mass, are responsible for producing both LH and Follicle-Stimulating Hormone (FSH).[17] The structure of LH consists of two non-covalently linked subunits: an alpha (α) subunit and a beta (β) subunit.[17] The α-subunit, comprising 92 amino acids, is structurally identical across several other glycoprotein hormones, including FSH, Thyroid-Stimulating Hormone (TSH), and human Chorionic Gonadotropin (hCG).[2] In contrast, the β-subunit, with its 121 amino acids, is unique to LH and confers the hormone's distinct biological specificity and function.[17] The combined molecular weight of the heterodimer is approximately 28 kDa.[17]

The shared nature of the α-subunit and the specificity of the β-subunit have profound implications for both diagnostics and therapeutics. For accurate diagnostic measurement, laboratory assays must specifically target the unique β-subunit to prevent cross-reactivity with other glycoprotein hormones, especially hCG, which can be present at very high concentrations during pregnancy.[6] From a therapeutic standpoint, the development of recombinant LH requires the precise co-expression and assembly of both subunits to form a biologically active hormone capable of binding to its specific receptor without inadvertently activating FSH or TSH pathways.[6]

Post-translational modification, specifically N-linked glycosylation at sites on both subunits (Asn-52 and Asn-78 on the α-subunit; Asn-30 on the β-subunit), is essential for the hormone's stability and biological activity. Studies have shown that while deglycosylated LH variants can still bind to the LH receptor, they fail to efficiently activate the downstream signaling cascade, rendering them biologically inert.[9]

The Hypothalamic-Pituitary-Gonadal (HPG) Axis

The synthesis and release of LH are meticulously regulated by the Hypothalamic-Pituitary-Gonadal (HPG) axis, a sophisticated neuroendocrine feedback system.[3] The process begins in the hypothalamus, which releases Gonadotropin-Releasing Hormone (GnRH) into the hypophyseal portal system in a distinct pulsatile fashion.[17] This pulsatility is critical; continuous GnRH exposure leads to the desensitization of pituitary receptors and a shutdown of gonadotropin release. The release of GnRH is itself modulated by upstream neurotransmitters, with kisspeptin being identified as a crucial positive regulator.[5]

Upon reaching the anterior pituitary, GnRH stimulates the gonadotroph cells to secrete both LH and FSH.[5] These hormones then travel through the bloodstream to the gonads (ovaries or testes), where they stimulate the production of sex steroids—estrogen and progesterone in females, and testosterone in males. These gonadal steroids, in turn, exert feedback control on the hypothalamus and pituitary. In males, testosterone provides a consistent negative feedback signal, maintaining stable LH levels.[4] In females, the feedback is more complex: for most of the menstrual cycle, estrogen and progesterone exert negative feedback to suppress LH secretion. However, at mid-cycle, sustained high levels of estrogen paradoxically switch to a positive feedback mechanism, triggering the massive LH surge that is essential for ovulation.[4]

This fundamental principle of the HPG axis—the opposing effects of pulsatile versus continuous GnRH stimulation—is strategically exploited for different therapeutic purposes. Fertility treatments aim to mimic or augment the natural pulsatile release of gonadotropins to induce ovulation.[23] Conversely, in hormone-sensitive cancers like prostate cancer, continuous administration of a long-acting LHRH analogue is used to downregulate pituitary receptors, shut down LH production, and induce a state of medical castration, thereby depriving the tumor of androgenic fuel.[15] This demonstrates how a deep understanding of the axis's physiology allows for its manipulation to achieve diametrically opposed clinical outcomes.

Mechanism of Action in Male and Female Reproductive Systems

Function in Females

In the female reproductive system, LH plays a dynamic role that changes throughout the menstrual cycle, operating under the "two-cell, two-gonadotropin" model. During the follicular phase (the first half of the cycle), LH targets the theca cells surrounding the developing ovarian follicles, stimulating them to produce androgens, primarily androstenedione.[9] These androgens diffuse into the adjacent granulosa cells, where, under the influence of FSH, the enzyme aromatase converts them into estradiol.[9]

As the dominant follicle matures and estradiol levels rise, they eventually reach a threshold that triggers the switch to positive feedback on the pituitary, causing the LH surge around day 14.[3] This dramatic, short-lived spike in LH is the direct and indispensable trigger for ovulation, inducing the rupture of the mature Graafian follicle and the release of the oocyte.[18]

Following ovulation, during the luteal phase, LH continues to act on the remaining follicular structure, stimulating its transformation into the corpus luteum.[5] The corpus luteum is a temporary endocrine gland that, under the influence of LH, produces large amounts of progesterone. Progesterone is critical for preparing the uterine endometrium for the potential implantation of a fertilized egg and for sustaining the early stages of pregnancy until the placenta can take over this function.[3]

Function in Males

In males, where it is also known as Interstitial Cell-Stimulating Hormone (ICSH), LH has a more constant, tonic function.[2] Its primary targets are the Leydig cells located in the interstitial tissue between the seminiferous tubules of the testes.[2] LH binding to its receptors on Leydig cells is the principal signal for the synthesis and secretion of testosterone, the main male androgen.[3] Testosterone is essential for initiating and maintaining spermatogenesis within the seminiferous tubules and is also responsible for the development and maintenance of secondary male sexual characteristics, such as increased muscle mass, a deeper voice, and the growth of facial and body hair.[3]

Cellular Signaling Pathway

At the cellular level, LH exerts its effects by binding to the LH/hCG receptor, a member of the G-protein coupled receptor (GPCR) superfamily located on the plasma membrane of theca and Leydig cells.[6] This ligand-receptor binding event activates an associated Gs protein, which in turn stimulates the enzyme adenylyl cyclase.[17] Adenylyl cyclase catalyzes the conversion of adenosine triphosphate (ATP) into the second messenger cyclic adenosine monophosphate (cAMP). The resulting increase in intracellular cAMP concentration activates Protein Kinase A (PKA). PKA then phosphorylates a variety of specific downstream intracellular proteins and transcription factors, which ultimately orchestrates the complex physiological actions of LH, most notably the expression of steroidogenic enzymes required for the synthesis of testosterone and progesterone.[17]

Pharmacological Formulations of Gonadotropin Therapy

The therapeutic application of LH is achieved through two distinct classes of pharmacological preparations: those derived from natural human sources and those produced via recombinant DNA technology.

Urinary-Derived Gonadotropins (Menotropins, hMG)

Menotropins, marketed under brand names such as Menopur and Repronex, are gonadotropin preparations extracted and purified from the urine of postmenopausal women.[7] Postmenopausal women have elevated levels of circulating gonadotropins due to the lack of negative feedback from ovarian hormones. These formulations contain a mixture of both FSH and LH activity, typically in a standardized 1:1 ratio (e.g., 75 IU of FSH and 75 IU of LH per vial), though some preparations may also contain small, variable amounts of hCG, which contributes to the overall LH bioactivity due to its shared receptor.[7]

The introduction of menotropins in the 1960s was a landmark achievement in reproductive medicine.[7] However, as biological extracts, these products have inherent clinical limitations. Their composition can exhibit batch-to-batch variability, and they contain other urinary proteins, which can lead to less predictable ovarian responses compared to highly purified recombinant products.[30] Furthermore, while modern purification techniques are highly effective, a theoretical risk of infectious agent transmission, although extremely low, remains a consideration with any human-derived biological product—a risk that is completely obviated by recombinant technology.[7]

Recombinant Human Luteinizing Hormone (Lutropin alfa)

Lutropin alfa (brand name: Luveris) is a recombinant human LH (r-hLH) produced using advanced recombinant DNA technology.[6] The human genes for the α- and β-subunits are inserted into Chinese Hamster Ovary (CHO) cell lines, which then synthesize and secrete the hormone.[9] This process yields an exceptionally pure preparation of LH that is structurally and functionally identical to endogenous human LH, ensuring high quality and batch-to-batch consistency.[8]

Lutropin alfa is supplied as a sterile, lyophilized powder in vials typically containing 75 IU, which are reconstituted with sterile water for subcutaneous injection.[9] It was the first, and remains the only, recombinant form of LH developed specifically for stimulating follicular development.[6] Although Luveris was discontinued from the U.S. market in 2012 for commercial reasons, it remains approved in other regions and serves as a critical therapeutic agent and an important benchmark for clinical research in reproductive endocrinology.[32]

Table 1: Comparison of LH-Containing Therapeutic Formulations

Feature	Menotropins (hMG)	Lutropin alfa (r-hLH)
Brand Examples	Menopur, Repronex, Pergonal	Luveris, Pergoveris (co-formulated with FSH)
Source	Purified from the urine of postmenopausal women	Recombinant DNA technology in Chinese Hamster Ovary (CHO) cells
Composition	Mixture of FSH and LH activity, may contain hCG	Pure LH (α and β subunits)
Purity	Contains other urinary proteins	Highly pure (>95%)
Consistency	Subject to batch-to-batch variability	High batch-to-batch consistency
Administration	Intramuscular (IM) or Subcutaneous (SC)	Subcutaneous (SC)

Clinical Application in the Management of Infertility

The primary clinical role of exogenous LH is in the treatment of infertility, specifically targeting dysfunctional ovulation. Its use is highly specific and requires careful patient selection and monitoring.

Indications for Use

The principal indication for therapy with lutropin alfa, in combination with FSH, is the stimulation of follicular development in adult women diagnosed with severe LH and FSH deficiency.[6] This condition, known as hypogonadotropic hypogonadism (WHO Group I anovulation), is characterized by impaired pituitary secretion of gonadotropins, leading to low endogenous serum LH levels (defined in clinical trials as <1.2 IU/L) and a lack of follicular development.[6] These women are typically amenorrhoeic (have no menstrual periods) and have low estrogen levels.[31]

Beyond this primary indication, LH, either as a therapeutic agent or as a diagnostic marker, is integral to various Assisted Reproductive Technology (ART) procedures, including in vitro fertilization (IVF).[7] Blood and urine tests measuring LH levels are routinely used to help diagnose the causes of infertility, monitor the ovarian response to stimulation, and predict the timing of ovulation to optimize chances of conception.[23]

Protocols for Controlled Ovarian Stimulation

In clinical practice, LH therapy is never used in isolation for ovulation induction. It is administered concomitantly with an FSH preparation (such as follitropin alfa) in a daily injection regimen.[6] A standard starting protocol involves daily subcutaneous injections of 75 IU of lutropin alfa alongside 75 to 150 IU of FSH.[31]

Treatment is highly individualized and is guided by meticulous monitoring of the patient's response. This involves serial transvaginal ultrasound examinations to measure the number and size of developing follicles, as well as regular blood tests to measure serum estradiol concentrations, which reflect follicular activity.[31] The dose of FSH may be adjusted at 7- to 14-day intervals based on this monitoring.[31]

Once an optimal response is achieved—typically defined as the presence of at least one mature follicle (e.g., ≥17 mm in diameter) and adequate estradiol levels—a single "trigger shot" of hCG (5,000-10,000 IU) or recombinant hCG (250 mcg) is administered 24 to 48 hours after the final LH/FSH dose.[31] This injection mimics the natural LH surge, inducing final oocyte maturation and ovulation. Following the trigger, the couple is advised on the optimal timing for intercourse or intrauterine insemination.[31] In many protocols, luteal phase support with supplemental progesterone is provided, as the absence of sustained luteotropic activity after ovulation can lead to premature failure of the corpus luteum and compromise the chances of successful implantation.[31]

Comparative Efficacy and Cost-Effectiveness in Assisted Reproductive Technology

The availability of both urinary-derived and recombinant gonadotropins has prompted numerous studies to compare their clinical efficacy and economic value in ART. The results are nuanced and highlight the importance of patient selection.

Clinical Trial Evidence

The body of evidence comparing recombinant LH (lutropin alfa) with urinary-derived menotropins (hMG) shows varied outcomes that appear highly dependent on the patient population being studied.[40] This underscores that the benefit of LH supplementation is not universal but is instead a targeted intervention for specific endocrine profiles.

In the core indicated population of women with profound LH deficiency (hypogonadotropic hypogonadism), LH supplementation is not merely beneficial but essential for achieving follicular development.[6] In this group, the question is not whether to use LH, but which formulation is optimal. For broader populations, the evidence is less clear. In unselected IVF populations, adding LH to a standard FSH protocol may not confer additional benefit, as endogenous LH levels are often sufficient.[8]

The data in poor ovarian responders are particularly complex. One prospective randomized trial in patients classified under the POSEIDON criteria as Group 4 (age ≥35 with poor ovarian reserve markers) found that supplementing an FSH protocol with hMG did not improve IVF outcomes compared to FSH monotherapy.[42] This suggests that in cases of diminished ovarian reserve, the limiting factor is the number of available follicles, a problem that cannot be overcome simply by adding more LH. In contrast, a 2002 randomized trial concluded that highly purified hMG was as effective as recombinant FSH for achieving ongoing pregnancy, with similar safety profiles, suggesting equivalency in certain contexts.[41] Ultimately, the clinical decision to supplement with LH must be based on a careful assessment of the patient's individual endocrine status, with the clearest benefit seen in those with a demonstrated LH deficiency.

Economic Analysis

Economic analyses have revealed a crucial dynamic: a higher upfront drug acquisition cost does not necessarily translate to a higher overall cost for a successful outcome. A cost-effectiveness analysis based on a trial that reported higher cumulative live birth rates (CLBR) with a recombinant FSH + recombinant LH protocol (64%) versus an r-FSH + hMG protocol (53%) provides a clear example.[10] While the total treatment cost per patient was higher for the all-recombinant group ($4550 vs. $4290), the higher success rate meant that the average cost

per live birth was significantly lower ($7059 for the recombinant group vs. $8052 for the hMG group).[10] A cost-effectiveness acceptability curve from this analysis showed that the recombinant combination had a 99% probability of being cost-effective at a willingness-to-pay threshold of approximately $18,500.[10]

Another analysis comparing r-FSH + r-LH to highly purified hMG (HP-HMG) found similar results. The recombinant strategy had a higher acquisition cost but also higher efficacy, resulting in a lower average cost per pregnancy (€3,990 vs. €5,440).[12] This demonstrates a key principle in health economics: the superior consistency and purity of recombinant products can lead to improved efficacy, which in turn drives cost-effectiveness by reducing the need for repeated, expensive ART cycles. A more expensive drug can represent a better value proposition for the healthcare system if it achieves the desired outcome more efficiently.

Safety Profile, Risk Management, and Contraindications

While generally well-tolerated, gonadotropin therapy carries significant risks that require careful management, the most prominent of which is Ovarian Hyperstimulation Syndrome.

Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is an iatrogenic complication resulting from an excessive response to hormonal stimulation during fertility treatments.[13] It is characterized by cystic enlargement of the ovaries and a fluid shift from the intravascular space into the third space, leading to ascites, pleural effusion, and hemoconcentration.[44] The pathophysiology is driven by an abnormal ovarian response to high levels of human chorionic gonadotropin (hCG), which binds to and activates the LH receptor, causing the release of vasoactive substances like Vascular Endothelial Growth Factor (VEGF) that increase vascular permeability.[14]

Symptoms range from mild (abdominal bloating, nausea, mild pain) to severe and potentially life-threatening (rapid weight gain, severe abdominal pain, shortness of breath, decreased urination, and thromboembolic events).[14] Women with Polycystic Ovary Syndrome (PCOS) or those who develop a large number of follicles during stimulation are at the highest risk.[13]

Prevention is the cornerstone of management. This involves meticulous monitoring with ultrasound and estradiol levels, using the lowest effective dose of gonadotropins, and employing strategies to mitigate risk in high-risk patients. These strategies include "coasting" (withholding gonadotropins for several days before the trigger shot), using a GnRH agonist instead of hCG to trigger ovulation (which induces a shorter, more physiological LH surge), and cryopreserving all embryos for transfer in a subsequent, unstimulated cycle (a "freeze-all" approach).[14]

Table 2: Clinical Management of Ovarian Hyperstimulation Syndrome (OHSS)

OHSS Severity	Key Symptoms	Recommended Management/Intervention
Mild	Mild abdominal pain, bloating, nausea	Avoid vigorous activity, maintain hydration with electrolyte-rich fluids, monitor daily weight, outpatient observation.
Moderate	Worsening abdominal pain and bloating, persistent nausea/vomiting, ultrasound evidence of ascites	As above, plus anti-nausea medication. Close monitoring for progression.
Severe	Rapid weight gain, severe abdominal pain, shortness of breath, decreased urine output, evidence of hemoconcentration or thromboembolism	Hospitalization required. Management includes IV fluids, paracentesis (drainage of abdominal fluid), thromboprophylaxis (e.g., blood thinners), and intensive monitoring of fluid balance and respiratory status.

Other Adverse Effects and Contraindications

Besides OHSS, other potential adverse effects of LH therapy include common, milder reactions such as pain, redness, or swelling at the injection site, headaches, and breast tenderness.[8] More significant risks inherent to successful ovarian stimulation include multiple gestation (twins, triplets, or higher-order multiples), which carries increased risks for both mother and babies, and a slightly increased risk of ectopic (tubal) pregnancy and adnexal torsion (twisting of the enlarged ovary).[33]

Absolute contraindications for LH therapy are clear and include known hypersensitivity to the product, pre-existing tumors of the hypothalamus or pituitary gland, and cancers of the ovary, uterus, or breast.[31] It is also contraindicated in patients with ovarian cysts of unknown origin and in conditions where a viable pregnancy is impossible, such as primary ovarian failure or significant uterine malformations.[31]

Long-Term Safety Considerations

The long-term safety of gonadotropin therapy, particularly concerning cancer risk, has been a subject of extensive research. To date, systematic reviews and meta-analyses have not found a conclusive association between the use of fertility drugs and an increased risk of breast, colon, or cervical cancer.[48] There is a signal for an increased risk of invasive and borderline ovarian tumors; however, this association is significantly confounded by the underlying conditions that lead to infertility, such as nulliparity (never having given birth) and endometriosis, which are themselves independent risk factors for ovarian cancer.[48] Therefore, it remains unclear whether the risk is attributable to the medications or the patient's baseline condition.

Separately, long-term follow-up studies of children treated with GnRH analogues for central precocious puberty have been largely reassuring, showing no significant adverse consequences on adult height, body mass index, bone mineral density, or subsequent reproductive function, though data are still accumulating.[52]

Future Directions and Emerging Therapeutic Landscapes

The field of gonadotropin therapy is evolving, with research focused on creating more patient-friendly formulations and exploring the role of the HPG axis in diseases beyond reproduction.

Novel Formulations and Delivery Systems

A significant limitation of current gonadotropin therapy is the treatment burden, which often requires patients to undergo daily subcutaneous injections for extended periods.[7] Future developments are aimed squarely at alleviating this burden. Research is underway to create more stable drug formulations, such as dry powders that are more resilient to temperature changes and can be reconstituted for use.[55]

A more transformative approach involves novel drug delivery systems. One promising area is the use of injectable, biocompatible hydrogel microbeads that encapsulate the hormone.[56] This technology is designed for slow, extended release of the active drug, which could potentially shift the administration schedule from daily to monthly self-injections. Such systems would not only improve patient convenience and adherence but could also provide more stable, physiological hormone levels by avoiding the daily peaks and troughs associated with frequent injections, potentially improving the safety profile.[56]

Expanded Indications

While LH is primarily associated with reproduction, its regulatory pathway is a target for a growing number of therapeutic areas. The established use of LHRH analogues to suppress LH and testosterone is a cornerstone of androgen deprivation therapy for prostate cancer and is also being investigated in hormone receptor-positive breast cancer.[15]

Perhaps the most forward-looking area of research is in neuroendocrinology. Emerging evidence suggests a link between the dysregulation of the HPG axis during menopause—a state characterized by high circulating LH levels—and the pathogenesis of age-related neurodegenerative disorders, including Alzheimer's disease.[16] This research posits that chronically elevated LH may have detrimental effects on the central nervous system. This opens an entirely new therapeutic frontier, suggesting that LH or its receptor could become a novel target for drugs aimed at preventing or modifying the course of neurodegeneration. This potential application fundamentally expands the perception of LH from a purely reproductive hormone to one with systemic and neurological significance, particularly in the context of aging.

Conclusion

Luteinizing Hormone is a fundamental glycoprotein hormone whose intricate role within the Hypothalamic-Pituitary-Gonadal axis is well-understood, governing steroidogenesis and gametogenesis in both sexes. This understanding has enabled its successful translation into therapeutic agents, primarily for the treatment of infertility due to anovulation, with a clear indication in women with hypogonadotropic hypogonadism.

The evolution from urinary-derived menotropins to highly pure and consistent recombinant formulations like lutropin alfa represents a significant pharmacological advance. While debates over comparative efficacy in broader patient populations continue, economic analyses suggest that the higher initial cost of recombinant products can be offset by superior cost-effectiveness, driven by higher success rates per treatment cycle.

The clinical use of LH therapy is effective but demands vigilant management. The risk of Ovarian Hyperstimulation Syndrome remains the most significant safety concern, mandating careful patient selection, individualized protocols, and proactive monitoring to mitigate its potentially severe consequences.

Looking forward, the therapeutic landscape for targeting the LH pathway is broadening. The immediate future promises more patient-centric delivery systems, such as long-acting injectable hydrogels, designed to reduce treatment burden and improve quality of life. In the longer term, the exploration of the HPG axis's role in non-reproductive systems, including its potential link to neurodegenerative diseases like Alzheimer's, signals a paradigm shift. This research may unlock novel therapeutic strategies, repositioning Luteinizing Hormone and its signaling pathway as a target of interest far beyond the field of reproductive medicine.

Works cited

1. Luteinising hormone (Luteinizing hormone) API Manufacturers | GMP-Certified Suppliers, accessed June 18, 2025, https://pharmaoffer.com/api-excipient-supplier/hormonal-agents/luteinising+hormone
2. luteinizing hormone - Drug Central, accessed June 18, 2025, https://drugcentral.org/drugcard/5601?q=M%20TRIMETHADIONE
3. Luteinizing Hormone: Levels, Function & Testing - Cleveland Clinic, accessed June 18, 2025, https://my.clevelandclinic.org/health/body/22255-luteinizing-hormone
4. Physiology, Luteinizing Hormone - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/30969514/
5. Luteinising hormone - You and Your Hormones, accessed June 18, 2025, https://www.yourhormones.info/hormones/luteinising-hormone/
6. Lutropin alfa: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed June 18, 2025, https://go.drugbank.com/drugs/DB00044
7. Menotropin - Wikipedia, accessed June 18, 2025, https://en.wikipedia.org/wiki/Menotropin
8. Recombinant follitropin alfa/lutropin alfa in fertility treatment - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2819896/
9. Luveris® (lutropin alfa for injection) - accessdata.fda.gov, accessed June 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21322lbl.pdf
10. A direct healthcare cost analysis of recombinant LH versus hMG ..., accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/38099955/
11. A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol | Request PDF - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/376555892_A_direct_healthcare_cost_analysis_of_recombinant_LH_versus_hMG_supplementation_on_FSH_during_controlled_ovarian_hyperstimulation_in_the_GnRH-antagonist_protocol
12. Full article: Cost-effectiveness analysis on the use of rFSH + rLH for the treatment of anovulation in hypogonadotropic hypogonadal women, accessed June 18, 2025, https://www.tandfonline.com/doi/full/10.2147/TCRM.S62351
13. Ovarian Hyperstimulation Syndrome (OHSS): Causes & Treatment - Cleveland Clinic, accessed June 18, 2025, https://my.clevelandclinic.org/health/diseases/17972-ovarian-hyperstimulation-syndrome-ohss
14. Ovarian hyperstimulation syndrome - Symptoms & causes - Mayo ..., accessed June 18, 2025, https://www.mayoclinic.org/diseases-conditions/ovarian-hyperstimulation-syndrome-ohss/symptoms-causes/syc-20354697
15. Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment - Karger Publishers, accessed June 18, 2025, https://karger.com/pha/article-pdf/85/2/110/3421018/000274486.pdf
16. Luteinizing Hormone Involvement in Aging Female Cognition: Not All Is Estrogen Loss, accessed June 18, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2018.00544/full
17. Physiology, Luteinizing Hormone - StatPearls - NCBI Bookshelf, accessed June 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK539692/
18. LHRH Protein | Luteinizing Hormone | lutropin Antigen - Prospec Bio, accessed June 18, 2025, https://www.prospecbio.com/lhrh
19. Lutropin alfa, Recombinant human iuteinizing hormone - Therapeutic Proteins, accessed June 18, 2025, https://therapeutic.creativebiomart.net/lutropin-alfa-recombinant-human-iuteinizing-hormone.html
20. Pharmacology Review(s) - accessdata.fda.gov, accessed June 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021322s000_Luveris_pharmr.pdf
21. Luteinizing hormone (LH): Functions, Levels, Ovulation - Ada Health, accessed June 18, 2025, https://ada.com/hormones/luteinizing-hormone/
22. Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2726078/
23. Female infertility - Diagnosis & treatment - Mayo Clinic, accessed June 18, 2025, https://www.mayoclinic.org/diseases-conditions/female-infertility/diagnosis-treatment/drc-20354313
24. Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment - Portal de Periódicos da CAPES, accessed June 18, 2025, https://www.periodicos.capes.gov.br/index.php/acervo/buscador.html?task=detalhes&id=W2087679214
25. Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/20130444/
26. The action of Luteinizing Hormone on males and females - Unacademy, accessed June 18, 2025, https://unacademy.com/content/neet-ug/study-material/biology/luteinizing-hormone/
27. Functions of Luteinizing hormone - Byjus, accessed June 18, 2025, https://byjus.com/biology/luteinizing-hormone/
28. Luteinizing hormone: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed June 18, 2025, https://go.drugbank.com/drugs/DB14741
29. Menotropins Monograph for Professionals - Drugs.com, accessed June 18, 2025, https://www.drugs.com/monograph/menotropins.html
30. A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection - PMC - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2768716/
31. Luveris, INN-lutropin alfa - European Medicines Agency, accessed June 18, 2025, https://www.ema.europa.eu/en/documents/product-information/luveris-epar-product-information_en.pdf
32. Luveris | European Medicines Agency (EMA), accessed June 18, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/luveris
33. Lutropin Alfa: Fertility Uses, Side Effects, Dosage - MedicineNet, accessed June 18, 2025, https://www.medicinenet.com/lutropin_alfa/article.htm
34. Lutropin Alfa: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed June 18, 2025, https://www.rxlist.com/lutropin_alfa/generic-drug.htm
35. Luveris, INN-lutropin alfa, accessed June 18, 2025, https://ec.europa.eu/health/documents/community-register/2015/20150424131830/anx_131830_en.pdf
36. Follicle stimulating hormone and luteinizing hormone (intramuscular route, subcutaneous route) - Mayo Clinic, accessed June 18, 2025, https://www.mayoclinic.org/drugs-supplements/follicle-stimulating-hormone-and-luteinizing-hormone-intramuscular-route-subcutaneous-route/description/drg-20062932
37. Luteinizing Hormone (Blood) - Content - Health Encyclopedia - University of Rochester Medical Center, accessed June 18, 2025, https://www.urmc.rochester.edu/encyclopedia/content?ContentTypeID=167&ContentID=luteinizing_hormone_blood
38. Luteinizing Hormone (LH) Levels Test: MedlinePlus Medical Test, accessed June 18, 2025, https://medlineplus.gov/lab-tests/luteinizing-hormone-lh-levels-test/
39. LUVERIS® Product Monograph Page 27 of 30 - EMD Serono, accessed June 18, 2025, https://medinfo.emdserono.ca/content/dam/web/healthcare/biopharma/medinfo/canada/pdf/Luveris_EngPatPM.pdf
40. IVF protocol efficacy in women with expected suboptimal response depending on ovary stimulation mode, accessed June 18, 2025, https://www.tandfonline.com/doi/pdf/10.1080/09513590.2021.2006526
41. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/292129336_Efficacy_and_safety_of_highly_purified_menotropin_versus_recombinant_follicle-stimulating_hormone_in_in_vitro_fertilizationintracytoplasmic_sperm_injection_cycles_a_randomized_comparative_trial
42. Human Menopausal Gonadotropins in Combination for Stimulation does not Improve IVF Outcomes in POSEIDON Group 4 Patients, When Compared to Recombinant Follicle Stimulating Hormone Alone: A Prospective Randomized, Non-Blinded, Controlled Pilot Trial - IMR Press, accessed June 18, 2025, https://www.imrpress.com/journal/CEOG/50/11/10.31083/j.ceog5011235/htm
43. Human Menopausal Gonadotropins in Combination for Stimulation does not Improve IVF Outcomes in POSEIDON Group 4 - IMR Press, accessed June 18, 2025, https://article.imrpress.com/journal/CEOG/50/11/10.31083/j.ceog5011235/545bd5e1b1482424160b4b65d0ae53ef.pdf
44. Ovarian Hyperstimulation Syndrome (OHSS) | Discover - You and Your Hormones, accessed June 18, 2025, https://www.yourhormones.info/explore/discover/ovarian-hyperstimulation-syndrome-ohss/
45. Ovarian hyperstimulation syndrome (OHSS) patient education fact sheet, accessed June 18, 2025, https://www.reproductivefacts.org/news-and-publications/fact-sheets-and-infographics/ovarian-hyperstimulation-syndrome-ohss/
46. Side effects of injectable fertility drugs (gonadotropins) - ReproductiveFacts.org, accessed June 18, 2025, https://www.reproductivefacts.org/news-and-publications/fact-sheets-and-infographics/side-effects-of-injectable-fertility-drugs-gonadotropins/
47. Follicle stimulating hormone and luteinizing hormone Advanced Patient Information, accessed June 18, 2025, https://www.drugs.com/cons/follicle-stimulating-hormone-and-luteinizing-hormone.html
48. Fertility drugs and cancer: a guideline (2024) | American Society for Reproductive Medicine, accessed June 18, 2025, https://www.asrm.org/practice-guidance/practice-committee-documents/fertility-drugs-and-cancer-a-guideline-2024/
49. Fertility treatment and breast-cancer incidence: meta-analysis | BJS Open | Oxford Academic, accessed June 18, 2025, https://academic.oup.com/bjsopen/article/6/1/zrab149/6526446
50. IVF and breast cancer: A systematic review and meta-analysis - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/251878105_IVF_and_breast_cancer_A_systematic_review_and_meta-analysis
51. Fertility drugs and ovarian cancer risk: a critical review of the literature - Νικόλαος Βλάχος, accessed June 18, 2025, https://www.nikolaosvlahos.gr/el/blog/fertility-drugs-and-ovarian-cancer-risk-a-critical-review-of-the-literature
52. Efficacy and Safety of Long-Acting Gonadotropin Releasing Hormone Analogs - JournalAgent, accessed June 18, 2025, https://jag.journalagent.com/z4/download_fulltext.asp?pdir=jcrpe&plng=eng&un=JCRPE-03206
53. Efficacy and Safety of Gonadotropin-Releasing Hormone Analog Treatment in Childhood and Adolescence: A Single Center, Long-Term Follow-Up Study | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic, accessed June 18, 2025, https://academic.oup.com/jcem/article/95/1/109/2835177?login=true
54. Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: A systematic review and meta-analysis - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/33387371/
55. (PDF) Stabilization of luteinizing hormone-releasing hormone in a dry powder formulation and its bioactivity - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/281912127_Stabilization_of_luteinizing_hormone-releasing_hormone_in_a_dry_powder_formulation_and_its_bioactivity
56. New advances in hormone replacement therapy set to transform care - Drug Target Review, accessed June 18, 2025, https://www.drugtargetreview.com/article/157556/new-advances-in-hormone-replacement-therapy-set-to-transform-care/
57. Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma Recruiting Phase 2 Trials for Luteinizing hormone (DB14741) - DrugBank, accessed June 18, 2025, https://go.drugbank.com/indications/DBCOND0162925/clinical_trials/DB14741?phase=2&status=recruiting